FOR RESEARCH USE ONLY
Established clinical literatureMetabolic research

Semaglutide

Long-acting GLP-1 receptor agonist researched for weight, glycaemic and cardiometabolic outcomes.

01GLP-1 signalling02Glycaemic control03Cardiometabolic outcomes
Molecular signature / semaglutide
Structural identity

31-amino-acid, albumin-binding GLP-1 analogue

Also known as

GLP-1 receptor agonist · GLP-1 analogue

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

Semaglutide is a 31-amino-acid GLP-1 analogue with 94% sequence homology to native GLP-1, modified with a C-18 fatty diacid chain enabling albumin binding and a approximately 7-day half-life. It is the most clinically validated peptide in the GLP-1 class, with extensive Phase 3 data across obesity, type 2 diabetes, cardiovascular, hepatic and neurological research areas.

The research question

Semaglutide is a long-acting incretin-mimetic compound with one of the most mature datasets in this library. Its week-long exposure profile makes titration, gastrointestinal tolerability and changes in body composition central research variables.

Section 02

Mechanism & research themes

Activates GLP-1R on pancreatic β-cells to enhance glucose-dependent insulin secretion and suppress glucagon, while acting on hypothalamic GLP-1 receptors to reduce appetite and delay gastric emptying.

01

Mean 14.9–17.4% body weight reduction at 2.4mg/week (STEP trials, 68 weeks)

02

20% MACE reduction in non-diabetic obese subjects (SELECT, NEJM 2023)

03

HbA1c reduction of 1.5–2.0% vs placebo (SUSTAIN program)

04

59% NASH resolution vs 17% placebo (Phase II, NEJM 2021)

05

Reduced Parkinson's / Alzheimer's incidence signals in GLP-1 RA users

06

Emerging research into addiction and compulsive-behaviour applications

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Established clinical literature

Semaglutide has a large randomised trial literature across glycaemic control, weight outcomes and cardiovascular endpoints. That evidence applies to studied formulations and populations, not arbitrary research preparations.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Standard research titration: 0.25mg weekly (weeks 1–4) → 0.5mg (weeks 5–8) → 1.0mg (weeks 9–12) → 1.7mg (weeks 13–16) → 2.4mg weekly maintenance. Subcutaneous (abdomen, thigh or upper arm). Research protocols typically 12–68 weeks.

Reported persistence

approximately 168 hours (approximately 7 days), supporting once-weekly dosing.

Calculator starting point

0.25 mg per reference dose

1 doses per week · 16-week cycle

2 mL default reconstitution volume

Titrate: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, ~4 weeks at each step.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate Semaglutide
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 5mg vial with 2mL bacteriostatic water for a 2.5mg/mL working concentration. Swirl gently and allow to sit 2–3 minutes; do not shake.

Storage reference

Lyophilised: 2–8°C (stable approximately 36 months frozen); short-term room-temperature use acceptable. Reconstituted: 2–8°C, do not freeze, use within 28 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

GI side effects (nausea, vomiting, diarrhoea, constipation) reported in 40–70% of STEP participants — dose-dependent and a leading driver of discontinuation.

L2

25–39% of total weight lost may be lean mass — concurrent resistance training and adequate protein intake are critical.

L3

FDA gastroparesis warning (2023); dose- and duration-dependent risk of pathologically delayed gastric emptying.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only